Introduction
============

Consistent with the worldwide obesity epidemic, overweight/obesity is now the most prevalent body composition abnormality in patients with COPD.[@b1-copd-13-3331],[@b2-copd-13-3331] In epidemiological studies, obesity is defined based on body mass index (BMI) but there is a need to refine the clinical evaluation of obesity by studying fat distribution.[@b3-copd-13-3331] For example, cardio-metabolic diseases, such as hypertension, coronary and peripheral artery diseases, and diabetes, are more closely associated to ectopic adiposity, in which fat accumulates in the abdomen or in normally lean organs such as the skeletal muscles, than to BMI.[@b4-copd-13-3331] As such, there is a growing interest to better characterize body fat distribution in patients with COPD and to evaluate whether it is associated with adverse health consequences. We and others have recently reported that ectopic fat accumulates in patients with COPD.[@b5-copd-13-3331]--[@b7-copd-13-3331] However, estimating to which extent ectopic adiposity is related to COPD from these studies is problematic because enrolled participants were not necessarily representative of the general population, thus introducing potential biases in the estimation of the magnitude of the problem.

COPD is also intimately associated with the occurrence of cardiovascular[@b8-copd-13-3331],[@b9-copd-13-3331] and metabolic diseases (insulin resistance and diabetes),[@b10-copd-13-3331],[@b11-copd-13-3331] leading to increased all-cause and cardiovascular mortality in patients with COPD,[@b6-copd-13-3331] which may even be more frequent than COPD-related deaths.[@b12-copd-13-3331] Again, conclusions about the association between impaired cardiometabolic heath and COPD may be influenced by selection biases in studies where participants were selected from existing patient databases or because of their interactions with medical teams. Considering the detrimental effects of ectopic adiposity on cardiometabolic health in the general population[@b4-copd-13-3331] and that this form of obesity could be increased in COPD,[@b5-copd-13-3331]--[@b7-copd-13-3331] the possibility exists that ectopic adiposity could also modulate cardiometabolic health in COPD and be responsible, in part, for the cardiometabolic comorbidities seen in COPD.

The present study was embedded in the Canadian Cohort Obstructive Lung Disease (CanCOLD) study, a prospective longitudinal study for COPD with random population sampling. The research questions were as follows: 1) does ectopic fat accumulate in individuals with COPD identified through random sampling of the population; 2) is ectopic fat accumulation associated with adverse cardiometabolic health consequences in this population?

Methods
=======

Study design and participants
-----------------------------

All CanCOLD participants in two CanCOLD study centers (Montreal and Quebec City) were recruited for this substudy. CanCOLD ([ClinicalTrials.gov](http://ClinicalTrials.gov): NCT00920348) is a longitudinal cohort study based on random population sampling over the age of 40 years in nine Canadian cities. CanCOLD study design and protocol have been previously reported.[@b13-copd-13-3331] Study participants underwent the standard CanCOLD assessment procedures which provide information about patients' characteristics (age, race, sex, smoking history), medical history, body weight and height, and pulmonary function. To assess for cardiometabolic comorbidities, subjects completed a standardized questionnaire where the following question was asked: "Has a doctor or other health care provider ever told you that you had any of the following conditions?": hypertension, diabetes, coronary artery disease (including myocardial infarction, angina, coronary artery bypass, and angioplasty), and peripheral artery disease (including stroke, claudication, and peripheral artery surgery).[@b13-copd-13-3331] In addition, hypertension, diabetes, and coronary artery disease were considered present in participants taking antihypertensive, antianginal, and antidiabetic medications. Study participants also completed specific procedures for the purpose of this substudy: 1) measurements of waist and hip circumferences, 2) blood sampling to determine glucose, lipid, adipokine, and high-sensitivity C-reactive protein (Hs-CRP) profiles, and 3) a computed tomography (CT) abdominal scan at L4--L5 level to quantify body composition. Chest CT, which is already a part of the routine CanCOLD procedures, was used to assess liver density and to quantify coronary artery calcification. All patients provided written informed consent and the study was approved by ethics committees of participating centers. CanCOLD steering and scientific committees approved the substudy protocol.

Study participants were divided according to the pulmonary function testing results: 1) control subjects with a post-bronchodilator FEV~1~\>80% predicted value and FEV~1~/FVC ratio≥0.7; 2) patients with COPD with a post-bronchodilator FEV~1~/FVC ratio\<0.7 were further classified according to the Global initiative for chronic Obstructive Lung Disease (GOLD) airflow limitation classification scheme into GOLD 1, with an FEV~1~≥80% predicted and GOLD 2+ with an FEV~1~\<80% predicted.

Body composition, liver density, and coronary artery calcification assessment
-----------------------------------------------------------------------------

Abdominal fat and muscle (psoas, paraspinal, and abdominal wall muscles) tissue cross-sectional areas and densities were quantified from the L4--L5 CT according to standardized techniques.[@b14-copd-13-3331] Images were analyzed using a specialized image analysis software (Slice-O-Matic; Tomovision, Montreal, QC, Canada), without knowledge of the clinical status of the subjects. Adipose and muscle tissue cross-sectional areas (cm^2^) were measured using an attenuation range of −190 to −30 Hounsfield units (HU) and of −29 to 130 HU, respectively. The mean attenuation value in HU of each structure was generated. Studies in animals have indicated that a lower attenuation (expressed as lower HU values) is associated with increased tissue fat content.[@b15-copd-13-3331] To avoid subjectivity in the separation between subcutaneous and visceral adipose tissues, these two fat tissues were separated from each other midway in the thickness of abdominal wall muscles. Body composition parameters were obtained with methodology commonly applied in our laboratory, with high levels of intra- and interobserver agreement.[@b5-copd-13-3331] Using the low-dose volumetric CT scan of the chest at full inspiration obtained in CanCOLD,[@b16-copd-13-3331] coronary artery calcification, a surrogate of coronary artery disease, and liver density,[@b17-copd-13-3331] a marker of fat liver infiltration, were quantified, according to standardized techniques.[@b18-copd-13-3331],[@b19-copd-13-3331]

Glucose, lipid, and adipokine profiles
--------------------------------------

Blood samples were collected in the morning after a 12-hour fast to determine the levels of glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, apolipoproteins (apoAI and apoB), triglycerides, Hs-CRP, hemoglobin A1c, and liver enzymes (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], gamma glutamyl-transferase \[GGT\]). All analyte levels were determined in plasma and whole blood using automated techniques (Roche Diagnostics, Hoffman-La Roche Ltd., Basel, Switzerland). Glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and liver enzymes (AST, ALT, GGT) were measured by enzymatic in vitro test. Apolipoproteins (apoAI and apoB) and Hs-CRP were measured using immunoturbidimetric assay. Insulin was determined using electrochemiluminescence immunoassay. Hemoglobin A1c was measured by turbidimetric inhibition immunoassay for hemolyzed whole blood. Plasma levels of adiponectin, leptin, ghrelin, and resistin were quantified using sensitive immunoassay kits, all available commercially (R&D Systems Inc., Minneapolis, MN, USA: adiponectin, leptin, and resistin; EMD Millipore, Billerica, MA, USA: ghrelin).

Statistical analyses
--------------------

Subjects' characteristics were compared between controls and the two groups of individuals with COPD, using ANOVA models for continuous variables and log-linear models for discrete variables. BMI, coronary artery calcification scores, total and HDL-cholesterol, triglycerides, leptin, adiponectin, ghrelin, resistin, and Hs-CRP were analyzed on a log~10~ scale because they had a log-normal distribution. Except for subjects' characteristics and lung function parameters appearing in [Table 1](#t1-copd-13-3331){ref-type="table"}, all remaining analyses were controlled for age, sex, and cumulative smoking history (pack-years). Between-group comparisons were conducted using a multivariate analysis of covariance model (MANCOVA), with age, sex, and pack-years included as covariates. When a significant effect of groups or subgroups was identified, univariate analyses of covariance models (ANCOVA) were performed to investigate which variables were different, followed by least significant difference-protected multiple comparisons to differentiate the subgroups. The proportion of individuals showing cardiometabolic comorbidities within each group was compared using a chi-squared test. Logistic regression models were used to document possible associations between cardiometabolic comorbidities (diabetes, hypertension, coronary artery disease, peripheral artery disease) as dependent variables and age, sex, cumulative tobacco exposure (pack-years), BMI, waist circumference, waist-to-hip ratio, FEV~1~ % predicted, and body composition parameters (visceral adipose tissue cross-sectional area, visceral adipose tissue attenuation, subcutaneous adipose tissue cross-sectional area, subcutaneous adipose tissue attenuation, muscle tissue cross-sectional area, muscle tissue attenuation, liver attenuation) as independent variables. The strength of the models to predict the presence of a specific comorbidity was evaluated by computing the area under the receiver operating characteristic (ROC) curve (C-statistic), with value \>0.9 (excellent), 0.80--0.90 (good), and \<0.80 (fair). *P*-values \<0.05 were considered statistically significant. Data analyses were performed using SAS version 9.4 (SAS Institute Inc., San Diego, CA, USA).

Results
=======

This CanCOLD substudy included 263 participants with a mean age of 65±9 years and, of whom, two-third were males ([Table 1](#t1-copd-13-3331){ref-type="table"}). Subjects were divided into control subjects with normal lung function (n=119), and GOLD 1 (n=70) and GOLD 2+ (n=74) individuals with COPD. There were no statistically significant between-subgroup differences for age, BMI, and waist-to-hip ratio ([Table 1](#t1-copd-13-3331){ref-type="table"}). The proportion of men was greater in GOLD 1 compared to the other two groups. The proportion of current smokers was greater in GOLD 2+ vs controls, while the cumulative tobacco exposure was greater in GOLD 2+ compared to controls and GOLD 1 patients.

Comorbidities at study entry and blood glucose, lipid, and adipokine profiles are presented in [Figure 1](#f1-copd-13-3331){ref-type="fig"} and [Table 2](#t2-copd-13-3331){ref-type="table"}, respectively. The prevalence of hypertension and coronary artery disease was greater in GOLD 2+ subjects compared to GOLD 1 and controls. Blood glucose, lipid, and adipokine profiles were similar across groups with the exception of leptin level which was higher in GOLD 2+ subjects compared to GOLD 1 and controls. There was a tendency for hemoglobin A1c to be higher in GOLD 2+ subjects compared to GOLD 1 subjects; this difference should be interpreted cautiously because the overall *P*-values from the MANCOVA analysis did not reach the 0.05 statistical threshold. Hs-CRP levels were higher in GOLD 2+ subjects in comparison to controls and GOLD 1.

BMI, waist-to-hip ratio, and CT-derived indices of body composition are depicted in [Figure 2](#f2-copd-13-3331){ref-type="fig"}. Despite exhibiting similar BMI and waist-to-hip ratio, subjects with GOLD 2+ COPD had a higher visceral adipose tissue cross-sectional area than subjects with GOLD 1 COPD (*P*=0.004). Consistent with these observations, mean muscle tissue attenuation was lower in GOLD 2+ vs the other groups, while muscle tissue cross-sectional area was similar across groups. Subcutaneous adipose tissue cross-sectional area was similar across groups. GOLD 1 individuals had a lower visceral adipose tissue cross-sectional area than controls (*P*=0.048), whereas the mean muscle tissue attenuation was similar between these two groups. Coronary artery calcification burden, assessed either by total score or by total volume, was similar across the three groups ([Table 3](#t3-copd-13-3331){ref-type="table"}). Similarly, hepatic density was also similar across groups.

Potential predictors of cardiometabolic comorbidities are presented in [Table 4](#t4-copd-13-3331){ref-type="table"}. CT-derived indices of ectopic adiposity emerged as strong predictors of hypertension, diabetes, and coronary artery disease, independent of age, sex, tobacco exposure, BMI, and waist-to-hip ratio ([Table 4](#t4-copd-13-3331){ref-type="table"}). Each 1-cm^2^ increase in the cross-sectional area of visceral adipose tissues was associated with a 1% increase in the odds of having hypertension or diabetes (both *P*\<0.001). Each 1-HU increase in muscle tissue attenuation was associated with a 25% reduction in the odds of having coronary artery disease (*P*\<0.001). According to the C-statistic, the predictive ability of the models was good to excellent (all three areas under the ROC curve\>0.8). No model could properly predict peripheral artery disease.

Discussion
==========

This CanCOLD substudy provides novel information about adiposity and its association with cardiometabolic health in COPD, which can be summarized as follows: 1) in comparison to GOLD 1, and after controlling for important risk factors, GOLD 2+ subjects featured increased ectopic fat accumulation as evidenced by increased visceral adipose tissue cross-sectional areas and reduced muscle tissue attenuation, a marker of muscle fat infiltration; 2) CT body composition parameters indicative of ectopic fat accumulation were associated with the presence of hypertension, diabetes, and coronary artery disease which were also more frequent in GOLD 2+ subjects, indicating that cardiometabolic health is intimately linked to body composition abnormalities in this population; and 3) the observation that visceral adipose tissues accumulate and that cardiometabolic comorbidities are more frequent in GOLD 2+ COPD subjects supports the notion that chronic diseases have a natural tendency to cluster within the same individuals.

A key methodological feature of this study is that participants were identified through random population sampling, and not from previous contact with medical teams or by advertising. The latter two recruitment strategies would likely lead to study enrollment of individuals having more important disease manifestations, which may not be representative of the general population. This could potentially bias conclusions regarding the association between ectopic adiposity, cardiometabolic comorbidities, and COPD. It has been shown that the burden of multimorbidity is greater in patients attending clinical care compared to the general population.[@b20-copd-13-3331] The clustering of ectopic fat accumulation, cardiometabolic comorbidities, and COPD found in the present random population sampling study is reflective of possible mechanistic associations between these conditions rather than the fact that individuals reaching medical care for one condition are more likely to be found with a second condition.

The present study offers a unique opportunity to evaluate the occurrence of ectopic adiposity and cardiometabolic comorbidities in mild COPD, and provides complementary information to large COPD cohort studies involving patients with more advanced diseases, such as ECLIPSE and COPDGene.[@b21-copd-13-3331],[@b22-copd-13-3331] We demonstrated that individuals with GOLD 1 COPD did not feature increased ectopic adiposity and cardiometabolic comorbidities compared to controls with normal lung function. Although the cross-sectional nature of the present study does not allow to reach a firm conclusion on the direction of the association between COPD and ectopic adiposity, the similarity in ectopic fat accumulation between GOLD 1 COPD and controls suggests that the development of overt airflow limitation precedes that of ectopic adiposity and cardiometabolic comorbidities. These results are in agreement with a study involving subjects newly diagnosed with COPD who were identified through lung cancer screening.[@b23-copd-13-3331]

Although CanCOLD was not designed to investigate in a mechanistic way the nature of the association between COPD, ectopic adiposity, and cardiometabolic comorbidities, the current findings may point toward certain possible pathophysiological scenarios of association, including shared risk factors such as aging, smoking, sedentary lifestyle, and poor nutritional habits. All analyses concerning these associations were adjusted for age, sex, and tobacco exposure, suggesting that the relationship among ectopic adiposity, cardiometabolic health, and COPD goes beyond these risk factors. Sedentary lifestyle that accompanies COPD progression[@b24-copd-13-3331] appears as an interesting intermediate link between COPD and ectopic adiposity[@b25-copd-13-3331],[@b26-copd-13-3331] but this factor was not explored in the present study. It is also conceivable that common pathophysiological pathways exist to favor the development of COPD and ectopic obesity, including genetic predisposition and generic responses to biological stresses such as low-grade chronic inflammation state.[@b27-copd-13-3331] Irrespective of the mechanisms, our data suggested that the development of ectopic adiposity and cardiometabolic comorbidities in individuals with COPD requires a certain degree of disease severity/activity that was evidenced in our population by more advanced airflow limitation and increased Hs-CRP levels.

Apart from the population sampling method, our study has other strengths. First, it was specifically designed to address the study questions in a prospective fashion and all participants in both centers contributing to the recruitment completed the specific evaluations related to the exploration of body fat distribution. Cardiometabolic profiling was also rather extensive, providing novel information on this topic. Increased ectopic adiposity in GOLD 2+ individuals was not associated with altered lipid profiles, perhaps due to the high proportion of participants on hypolipidemic agents. Higher leptin and Hs-CRP levels and the tendency for elevated hemoglobin A1C in GOLD 2+ subjects were consistent with the accumulation of visceral fat and higher cardiometabolic risk in GOLD 2+ individuals.[@b4-copd-13-3331]

One potential limiting factor, however, is the fact that the study was limited to two CanCOLD centers. It would nevertheless be of interest to examine if the current findings also apply to the larger CanCOLD population. Another limitation is the cross-sectional nature of the data collection. The longitudinal follow-up of CanCOLD is currently in progress and this will eventually allow studying the interactions between the longitudinal changes in body composition and cardiometabolic health in this population. We acknowledge that comorbidities were only assessed from standardized questionnaires and current medications and not from objectively measured physiological or biological criteria. Despite its limitations, this method of assessing comorbidities has been previously validated[@b28-copd-13-3331] and is used in large epidemiological studies.[@b29-copd-13-3331]

Obesity is now the most common body composition abnormality in COPD.[@b1-copd-13-3331],[@b2-copd-13-3331] COPD is also commonly associated with cardiovascular diseases,[@b30-copd-13-3331] hypertension,[@b31-copd-13-3331] metabolic syndrome,[@b32-copd-13-3331],[@b33-copd-13-3331] and diabetes.[@b34-copd-13-3331] We also know that cardiovascular diseases are an important cause of mortality in COPD.[@b6-copd-13-3331],[@b12-copd-13-3331] As such, cardiometabolic health should be a primary concern in patients with COPD and further work should be conducted to investigate how to best improve this important aspect of general health in patients with COPD.[@b35-copd-13-3331]

Excess ectopic adiposity has been pathologically associated with the development of cardiometabolic disorders in the general population.[@b4-copd-13-3331] Likewise, we report that body composition parameters are associated with cardiometabolic comorbidities in this population of subjects with COPD. Similar findings were also reported from the ECLIPSE cohort.[@b5-copd-13-3331] We extend these findings by reaching similar conclusion in patients with milder form of COPD, highlighting the necessity of addressing early in the disease process the issue of cardiometabolic health in COPD.

Cardiometabolic consequences of obesity are largely attributable to an excess of ectopic adipose tissue accumulating in the abdomen, rather than to subcutaneous "healthy" fat accumulation.[@b4-copd-13-3331] Our findings that indices of fat distribution, and not BMI, predict of cardiometabolic comorbidities are in agreement with these notions. Increased ectopic adiposity in GOLD 2+ individuals was not evidenced by "traditional" clinical measures such as BMI or waist-to-hip ratio which were similar across the groups. These findings may have implications about how cardiometabolic health is evaluated in COPD. Another interesting finding is the association between intra-abdominal muscle density and coronary artery disease, which was also reported in ECLIPSE.[@b5-copd-13-3331] Reduced muscle density in these two studies is consistent with the MRI evidence of intramuscular fat accumulation in COPD reported by other investigators.[@b36-copd-13-3331],[@b37-copd-13-3331] Ectopic fat accumulation in the skeletal muscle may influence muscle metabolism, leading to a cascade of reduced fat oxidation and insulin resistance, linking muscle metabolic abnormalities to cardiovascular comorbidities.[@b38-copd-13-3331]

A notable negative finding of this study is the absence of increased coronary artery calcification in subjects with COPD compared with controls. This finding is at variance with previous reports from ECLIPSE.[@b5-copd-13-3331],[@b39-copd-13-3331] This discrepancy between studies may lie in differences in how participants were recruited and in the severity of airflow limitation in study participants; for example, ECLIPSE mostly involved subjects with GOLD 2--4 COPD. Furthermore, coronary artery calcification reflects only one aspect of coronary artery disease. It is possible that the well-established link between ectopic adiposity and coronary artery disease involves other aspects such as the atherosclerotic plaque composition and fragility to rupture. Considering the general association of intra-abdominal fat accumulation with liver fat accumulation,[@b40-copd-13-3331] we expected to find reduced liver density in GOLD 2+ COPD individuals compared to controls. However, the association between intra-abdominal fat accumulation and liver fatty infiltration is not universal as dissociation could exist between these two fat depots.[@b41-copd-13-3331]

Conclusion
==========

Our study, based on random population sampling confirms a strong association between ectopic fat accumulation and impaired cardiometabolic health in COPD. These findings point to a clustering of chronic respiratory and cardiometabolic diseases in susceptible individuals and to the necessity of addressing cardiometabolic health early in the disease process of individuals with COPD.
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![Proportion of subjects in each group with a diagnosis of hypertension (**A**), diabetes, (**B**), coronary artery disease (**C**), and peripheral artery disease (**D**).\
**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; NS, not significant.](copd-13-3331Fig1){#f1-copd-13-3331}

![Group mean values±SD for body mass index (**A**), waist-to-hip ratio (**B**), muscle tissue cross-sectional area (muscle tissue CSA; **C**), muscle tissue attenuation (**D**), visceral adipose tissue CSA (**E**), visceral adipose tissue attenuation (**F**), subcutaneous adipose tissue CSA (**G**), and total adipose tissue CSA (**H**), in control subjects (open bars) and subjects with Global initiative for chronic Obstructive Lung Disease (GOLD) 1 (gray bars) and 2+ (black bars) COPD.\
**Abbreviations:** NS, not significant; CSA, cross-sectional tissue area; HU, Hounsfield units.](copd-13-3331Fig2){#f2-copd-13-3331}

###### 

Baseline characteristics by group[a](#tfn1-copd-13-3331){ref-type="table-fn"}

                                      Control subjects (n=119)   GOLD 1 COPD (n=70)   GOLD 2 COPD (n=74)   *P*-value Overall[b](#tfn2-copd-13-3331){ref-type="table-fn"}   *P*-value GOLD 1 vs controls   *P*-value GOLD 2 vs controls   *P*-value GOLD 1 vs GOLD 2
  ----------------------------------- -------------------------- -------------------- -------------------- --------------------------------------------------------------- ------------------------------ ------------------------------ ----------------------------
  Age (years)                         64.5±9.0                   66.4±9.9             63.9±8.8             0.221                                                           0.361                          0.895                          0.234
  Male, n (%)                         73 (61)                    54 (77)              39 (53)              0.007                                                           0.023                          0.238                          0.002
  BMI (kg/m^2^)                       27.2±4.9                   26.3±3.6             27.4±5.6             0.322                                                           0.484                          0.908                          0.331
  Waist-to-hip ratio                  0.93±0.09                  0.94±0.07            0.94±0.10            0.403                                                           0.464                          0.573                          0.987
  Current smokers, n (%)              12 (10)                    15 (21)              24 (32)              0.003                                                           0.104                          0.0004                         0.247
  Former smokers, n (%)               70 (59)                    37 (53)              37 (50)                                                                                                                                            
  Never smokers, n (%)                37 (31)                    18 (26)              13 (18)                                                                                                                                            
  Pack/year                           16±18                      21±24                37±29                \<0.001                                                         \<0.334                        \<0.001                        \<0.001
  Pulmonary function                                                                                                                                                                                                                     
   Post-BD FEV~1~ (L)                 2.95±0.79                  2.80±0.74            1.79±0.63            \<0.001                                                         0.409                          \<0.001                        \<0.001
   Post-BD, FEV~1~, % predicted       102±13                     95±12                64±13                \<0.001                                                         \<0.001                        \<0.001                        \<0.001
   Post-BD FVC (L)                    3.83±1.04                  4.37±1.10            3.17±0.96            \<0.003                                                         \<0.001                        \<0.001                        \<0.001
   Post-BD FVC, % predicted           122±17                     136±22               104±18               \<0.001                                                         \<0.001                        \<0.001                        \<0.001
   Post-BD FEV~1~/FVC, %              77±4                       64±5                 56±9                 \<0.001                                                         \<0.001                        \<0.001                        \<0.001
  Medication at baseline                                                                                                                                                                                                                 
   Short-acting BD, n (%)             2 (1.7)                    5 (7.1)              19 (26.7)            \<0.001                                                         0.060                          \<0.001                        0.002
   Long-acting BD, n (%)              1 (0.8)                    0 (0)                1 (1.4)              0.5075                                                          0.335                          0.737                          0.247
   Inhaled CS, n (%)                  3 (0.3)                    7 (10.0)             26 (35.1)            \<0.001                                                         0.030                          \<0.001                        \<0.001
   ACE/ARB, n (%)                     22 (18.4)                  14 (20.0)            23 (31.1)            0.117                                                           0.799                          0.046                          0.127
   β-Blockers, n (%)                  9 (7.6)                    4 (5.7)              10 (13.5)            0.228                                                           0.623                          0.183                          0.109
   Statins, n (%)                     28 (23.5)                  18 (25.7)            20 (27.0)            0.854                                                           0.736                          0.586                          0.858
   Other hypolipidemic drugs, n (%)   4 (3.3)                    1 (1.4)              2 (2.7)              0.704                                                           0.403                          0.796                          0.589
   Oral hypoglycemic agents, n (%)    9 (7.6)                    4 (5.7)              6 (8.1)              0.836                                                           0.623                          0.891                          0.571

**Notes:**

Values are mean±SD.

*P*-test for the global effect of group GOLD with post hoc comparisons done with protected LSD.

**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BD, bronchodilator; BMI, body mass index; CS, corticosteroids; LSD, least significant difference method.

###### 

Blood glucose, lipid, adipokine, and Hs-CRP profiles[a](#tfn4-copd-13-3331){ref-type="table-fn"}

                               Control subjects (n=119)   GOLD 1 COPD (n=70)   GOLD 2 COPD (n=74)   *P*-value Overall[b](#tfn5-copd-13-3331){ref-type="table-fn"}   *P*-value GOLD 1 vs controls   *P*-value GOLD 2 vs controls   *P*-value GOLD 1 vs GOLD 2
  ---------------------------- -------------------------- -------------------- -------------------- --------------------------------------------------------------- ------------------------------ ------------------------------ ----------------------------
  Glucose (mmol/L)             5.8±1.3                    5.7±1.3              6.0±1.4              0.268                                                           0.483                          0.285                          0.106
  Insulin (pmol/L)             130±168                    117±170              120±176              0.859                                                           0.616                          0.700                          0.931
  HBA1C (%)                    5.7±0.6                    5.6±0.6              5.8±0.6              0.120                                                           0.327                          0.170                          0.040
  Total cholesterol (mmol/L)   4.89±1.13                  5.11±1.14            4.92±1.19            0.400                                                           0.184                          0.831                          0.343
  LDL-cholesterol (mmol/L)     2.77±1.00                  2.96±1.01            2.74±1.05            0.375                                                           0.218                          0.845                          0.218
  HDL-cholesterol (mmol/L)     1.47±0.45                  1.51±0.45            1.54±0.47            0.624                                                           0.535                          0.360                          0.777
  Triglycerides (mmol/L)       1.43±0.73                  1.42±0.74            1.44±0.77            0.994                                                           0.986                          0.926                          0.922
  Apolipoprotein B (g/L)       0.92±0.25                  0.92±0.26            0.92±0.27            0.977                                                           0.836                          0.987                          0.870
  Apolipoprotein A1 (g/L)      1.56±0.28                  1.59±0.28            1.63±0.29            0.224                                                           0.473                          0.09                           0.356
  GGT (U/L)                    29.8±26.3                  23.2±26.7            29.3±27.7            0.231                                                           0.101                          0.910                          0.191
  ALT (U/L)                    20.9±10.2                  18.2±10.1            22.2±10.7            0.065                                                           0.076                          0.413                          0.025
  AST (U/L)                    24.7±7.3                   23.2±7.34            25.5±7.7             0.218                                                           0.207                          0.487                          0.090
  Leptin (ng/mL)               12.1±11.4                  9.0±11.6             14.3±12.0            0.033                                                           0.078                          0.229                          0.010
  Adiponectin (ng/mL)          7.7±4.8                    9.1±4.9              9.0±5.0              0.098                                                           0.068                          0.087                          0.966
  Leptin/adiponectin           2.28±2.89                  1.32±2.91            2.33±3.01            0.057                                                           0.027                          0.905                          0.046
  Resistin (ng/mL)             6.98±3.15                  6.91±3.19            7.00±3.30            0.984                                                           0.883                          0.970                          0.873
  Ghrelin (pg/mL)              551±651                    656±663              670±685              0.407                                                           0.294                          0.254                          0.906
  Hs-CRP (mg/L)                1.82±3.11                  1.91±3.15            3.38±3.26            0.004                                                           0.845                          0.002                          0.007

**Notes:**

Values are mean±SD corrected for age, sex, and tobacco exposure (pack-years).

*P*-test for the global effect of group GOLD with post hoc comparisons done with protected LSD.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl-transferase; GOLD, Global initiative for chronic Obstructive Lung Disease; HBA1C, glycosylated hemoglobin; Hs-CRP, high-sensitivity C-reactive protein.

###### 

Coronary artery calcification and liver density[a](#tfn7-copd-13-3331){ref-type="table-fn"}

                                   Control subjects (n=119)   GOLD 1 COPD (n=70)   GOLD 2 COPD (n=74)   *P*-value Overall[b](#tfn8-copd-13-3331){ref-type="table-fn"}   *P*-value GOLD 1 vs controls   *P*-value GOLD 2 vs controls   *P*-value GOLD 1 vs GOLD 2
  -------------------------------- -------------------------- -------------------- -------------------- --------------------------------------------------------------- ------------------------------ ------------------------------ ----------------------------
  Coronary artery calcification                                                                                                                                                                                                       
   Agatston total calcium score    352±512                    270±520              342±550              0.557                                                           0.294                          0.911                          0.429
   Agatston total calcium volume   287±411                    223±417              283±442              0.607                                                           0.337                          0.946                          0.451
  Fat liver infiltration                                                                                                                                                                                                              
   Liver density (HU)              58.4±10.0                  59.1±10.0            58.2±10.4            0.866                                                           0.655                          0.905                          0.622

**Notes:**

Values are mean±SD corrected for age, sex, and tobacco exposure (pack-years).

*P*-test for the global effect of group GOLD with post hoc comparisons done with protected LSD.

**Abbreviations:** GOLD, Global initiative for chronic Obstructive Lung Disease; HU, Hounsfield units; LSD, least significant difference method.

###### 

Predictors of cardiovascular comorbidities in multiple regression analyses

                                  Estimate   SE      Odds ratio   95% CI         *P*-value   C-statistic
  ------------------------------- ---------- ------- ------------ -------------- ----------- -------------
  Hypertension                                                                               0.83
   VAT CSA (cm^2^)                0.011      0.002   1.011        1.007--1.015   \<0.001     
   Age (years)                    0.093      0.021   1.097        1.053--1.142   \<0.001     
   Post BD, FEV~1~, % predicted   −0.020     0.008   0.981        0.965--0.997   0.0177      
  Diabetes                                                                                   0.83
   VAT CSA (cm^2^)                0.010      0.002   1.010        1.006--1.014   \<0.001     
   SCAT attenuation (HU)          0.067      0.027   1.070        1.016--1.127   0.002       
   Age (years)                    0.059      0.026   1.060        1.009--1.115   0.0216      
  Coronary artery disease                                                                    0.86
   MT attenuation (HU)            −0.276     0.069   0.759        0.662--0.869   \<0.001     
   Sex, male                      3.042      1.111   20.9         2.4--185       0.0062      

**Abbreviations:** BD, bronchodilator; C-statistic, area under the ROC curve; ROC, receiver operating characteristic; VAT, visceral adipose tissue; FEV~1~, forced expiratory volume in 1 s; CSA, cross-sectional tissue area; HU, Hounsfield units; MT, muscle tissue; SCAT, subcutaneous adipose tissue.
